Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of ARIAD Pharmaceuticals Inc (NASDAQ: ARIA) acted responsibly on behalf of investors’ profitability in the planned $5.2 billion sale to Takeda Pharmaceutical Company Limited.

On January 9, 2017, ARIAD Pharmaceuticals Inc (NASDAQ: ARIA) and Takeda Pharmaceutical Company Limited announced that they had entered into a merger agreement. Under the terms of the merger agreement, Takeda will offer ARIAD shareholders $24.00 per share in cash for all outstanding shares.    

Based in Cambridge, Massachusetts, and founded in 1991 ARIAD Pharmaceuticals Inc an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients internationally.

The investigation focuses on whether NASDAQ: ARIA investors received the highest price and whether the directors of ARIAD Pharmaceuticals Inc acted in the best interest of ARIAD Pharmaceuticals Inc company and its shareholders.   

If you purchased ARIAD Pharmaceuticals Inc (NASDAQ: ARIA) prior to January 9, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185